242 results on '"Masuda, Noriyuki"'
Search Results
2. Effect of ASP2205 fumarate, a novel 5-HT2C receptor agonist, on urethral closure function in rats
3. The role of prophylactic cranial irradiation for patients with small-cell lung cancer
4. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
5. Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia
6. Potentiation of Muscarinic M3Receptor Activation through a New Allosteric Site with a Novel Positive Allosteric Modulator ASP8302
7. Two Types of Cation Channel Activated by Stimulation of Muscarinic Receptors in Guinea-Pig Urinary Bladder Smooth Muscle
8. Architecture and design of an open ATE to incubate the development on third-party instruments
9. Flow Cytometric Detection of Small Cell Lung Cancer Cells with Aberrant CD45 Expression in Micrometastatic Bone Marrow
10. Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells
11. Differential expressions of cyclin A and the retinoblastoma gene product in histological subtypes of lung cancer cell lines
12. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung
13. Relapse of Stage I Small Cell Lung Cancer Ten or More Years after the Start of Treatment
14. Drug Interaction Between Gefitinib and Warfarin
15. Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders
16. An individual patient data meta-analysis of adjuvant immunochemotherapy with OK-432 after curative resection for gastric cancer
17. Final results of phase III study of irinotecan (CPT-11) plus cisplatin (CDDP) versus vindesine (VDS) plus CDDP versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC).
18. Additional file 2: of Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
19. Prognostic significance of IMMT expression in surgically‐resected lung adenocarcinoma
20. Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
21. Safety and effectiveness of alectinib in a real‐world surveillance study in patients withALK‐positive non–small‐cell lung cancer in Japan
22. Additional file 1: of Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604
23. Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
24. How should we exploit TAS-102?
25. Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation
26. A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
27. Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report
28. S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma
29. Additional file 3: Figure S1. of Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer
30. Additional file 1: Table S1. of Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer
31. Additional file 2: Table S2. of Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer
32. Additional file 4: Figure S2. of Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer
33. S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma
34. The role of prophylactic cranial irradiation for patients with small-cell lung cancer
35. Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease
36. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604
37. Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status
38. Pneumothorax during Pemetrexed Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report and Literature Review
39. Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature
40. Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers
41. Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer
42. P2.02-027 A Randomized Phase II Trial of S-1 plus Cisplatin or Docetaxel plus Cisplatin with Concurrent Thoracic Radiotherapy for Stage III NSCLC: TORG1018
43. A Mapping of Intra Research Park Networking Toward Efficient Utilization of Social Capital in Science Driven Innovation
44. Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan.
45. Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer
46. Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib
47. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer
48. Clinicopathological Significance of S100A10 Expression in Lung Adenocarcinomas
49. Endobronchial involvement of mantle cell lymphoma: A case report
50. P2-099 - How should we exploit TAS-102?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.